SAN DIEGO, Jan. 27, 2020 /PRNewswire-PRWeb/ -- Cytonus Therapeutics Inc. today announced the appointment of Christopher Thorne as Chairman. Thorne is a noted investor, tech entrepreneur, and former senior management consultant at McKinsey & Company who holds three Harvard degrees. He serves as Executive Chairman of Broadline Capital, the global alternative investment firm.
"Chris Thorne has exceptional business acumen with a proven track record in developing purpose-led businesses, driving innovation, and reinforcing a commitment to corporate responsibility," commented Cytonus' Founder and CEO, Remo Moomiaie-Qajar, MD. "He has extensive directorship experience at both publicly-listed corporations and privately-held ventures, as well as 501(c)(3) nonprofit organizations. All of these attributes, combined with his excellent people engagement and strategic insight, gives us confidence that Chris will help build a strong culture as we work together toward our shared vision for the Company and accelerate the development of our innovative platform of products to improve the health and lives of people across the globe."
"Cytonus is delighted to have appointed Chris Thorne as our Chairman after a thorough and rigorous selection process," commented Cytonus' Founder and Chief Scientific Officer, Richard Klemke, PhD. "Chris is an outstanding leader who brings vast experience across multiple industries, from his career at McKinsey & Company, to his accomplishments as a visionary entrepreneur, and his success as an astute investor."
Mr. Thorne will lead Cytonus' corporate board of directors and will serve as an independent non-executive director for the company.
About Cytonus Therapeutics Inc.
Cytonus Therapeutics Inc. is the cell-based platform technology company whose next-generation Adoptive Cellular Therapy (ACT) technologies have a wide range of medical applications across multiple therapeutic areas. Cytonus is developing a vast platform of proprietary immunotherapeutic products to cure a wide range of medical conditions including difficult-to-treat cancers and inflammatory diseases, and to improve patient outcomes. Its portfolio of inventions addresses the recognized limitations of existing cell-based therapies. Its proprietary pipeline of Cargocyte™ technologies are cellular-engineered enucleated transporters of a multiplicity of therapeutic payloads to tissue in selective, potent, and controllable off-the-shelf cellular therapies for treating numerous targeted diseases. Cytonus' new category-creating technologies are expected to transform how cancers and other diseases will be treated in the future and have the potential to improve the health and lives of millions of people around the world. For more information, please visit the Cytonus website at https://Cytonus.com and follow our LinkedIn and Twitter feeds at: @Cytonus.
Statements in this news release relating to Cytonus' plans and strategies, new and existing products and technologies, anticipated clinical and regulatory pathways, and markets for its products, are forward-looking statements. The words "believe," "expect," "anticipate," "estimate," "project," and similar expressions identify forward-looking statements that speak only as of the date hereof. Such statements involve risks and uncertainties that could cause actual results to differ materially from anticipated results due to many factors, including regulatory and development risks. Cytonus undertakes no obligation to publicly update or revise any forward-looking statements. This news release is neither an offer to sell, nor the solicitation of any offer to purchase, any security.
Follow Cytonus on LinkedIn and Twitter at: @Cytonus.
SOURCE Cytonus Therapeutics Inc.
Share this article